NCT04541108 2024-04-18Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer TherapiesPresage BiosciencesPhase EARLY_PHASE1 Recruiting15 enrolled
NCT03329950 2024-03-28A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCelldex TherapeuticsPhase 1 Completed132 enrolled
NCT02376699 2023-05-01Safety Study of SEA-CD40 in Cancer PatientsSeagen Inc.Phase 1 Terminated159 enrolled
NCT03841110 2023-05-01FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFate TherapeuticsPhase 1 Completed37 enrolled
NCT02178722 2022-02-14Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersIncyte CorporationPhase 1/2 Completed444 enrolled 19 charts
NCT01986426 2018-10-03LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or PembrolizumabLytix Biopharma ASPhase 1 Completed80 enrolled